SI1107795T1 - Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis - Google Patents

Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis

Info

Publication number
SI1107795T1
SI1107795T1 SI9930205T SI9930205T SI1107795T1 SI 1107795 T1 SI1107795 T1 SI 1107795T1 SI 9930205 T SI9930205 T SI 9930205T SI 9930205 T SI9930205 T SI 9930205T SI 1107795 T1 SI1107795 T1 SI 1107795T1
Authority
SI
Slovenia
Prior art keywords
thiomolybdate
carbohydrate
cancer
preventing
rheumatoid arthritis
Prior art date
Application number
SI9930205T
Other languages
English (en)
Slovenian (sl)
Inventor
George Brewer
Sofia D. Merajver
Dimitri The University of Michigan COUCOUVANIS
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Priority claimed from EP99952903A external-priority patent/EP1107795B1/fr
Publication of SI1107795T1 publication Critical patent/SI1107795T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI9930205T 1998-09-04 1999-09-03 Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis SI1107795T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9910398P 1998-09-04 1998-09-04
US10175998P 1998-09-25 1998-09-25
EP99952903A EP1107795B1 (fr) 1998-09-04 1999-09-03 Thiomolybdate associe a au moins un hydrate de carbone, et son utilisation dans la prevention et le traitement de maladies caracterisees par une vascularisation anormale, telles que le cancer, la degenerescence maculaire de type exsudatif, l'arthrite rhumatoide
PCT/US1999/020374 WO2000013712A2 (fr) 1998-09-04 1999-09-03 Methodes et compositions pour la prevention ou le traitement du cancer

Publications (1)

Publication Number Publication Date
SI1107795T1 true SI1107795T1 (en) 2003-06-30

Family

ID=27240352

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930205T SI1107795T1 (en) 1998-09-04 1999-09-03 Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis

Country Status (2)

Country Link
EP (1) EP1234585A3 (fr)
SI (1) SI1107795T1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
WO2000018392A1 (fr) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine-oxydase: antagonistes et inhibiteurs
AU2003225442B2 (en) 2002-03-08 2010-02-04 Philera New Zealand Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US7888389B2 (en) 2002-07-23 2011-02-15 The Regents Of The University Of Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
WO2004017956A1 (fr) * 2002-08-20 2004-03-04 Protemix Corporation Limited Formes posologiques et traitements s'y rapportant
AU2005281353A1 (en) 2004-07-19 2006-03-16 Philera New Zealand Limited Synthesis of triethylenetetramines

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230131T2 (de) 1991-07-03 2000-03-02 Otsuka Pharmaceutical Co., Ltd. Apoptoseregulator
US5464833A (en) 1992-08-19 1995-11-07 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
NZ254646A (en) 1992-08-19 1997-06-24 Merrell Dow Pharma Inhibition of angiogenesis by administration of a polyamide and a polyurea
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
NO941135L (no) 1993-04-01 1994-10-03 Daiichi Seiyaku Co Tiazolpyrimidin derivater
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5622829A (en) 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5618925A (en) 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US5605826A (en) 1994-06-10 1997-02-25 Panorama Research, Inc. 24 kilodalton cytoplasmic protease activating DNA fragmentation in apoptosis
US5693473A (en) 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5710001A (en) 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5709999A (en) 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5571523A (en) 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
US5654155A (en) 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene

Also Published As

Publication number Publication date
EP1234585A3 (fr) 2004-01-21
EP1234585A2 (fr) 2002-08-28

Similar Documents

Publication Publication Date Title
ZA988572B (en) Narrow MWD, compositionally optimized ethylene interpolymer composition, process for making the same and article made therefrom.
AU8749198A (en) Deodorant and antimicrobial water absorbent, process for the production thereof and absorbent articles
ZA200005329B (en) Organic Articles.
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
EP0685233A3 (fr) Thieno 1,5 benzodiazepine pour le traitement des troubles gastrointestinaux.
ZA200108530B (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents.
ZA991664B (en) 3,6-ketal and enol ether macrolide antibiotics.
ZA200107910B (en) Sizing composition.
ZA984647B (en) Dextran production.
EP0664516A3 (fr) Réseau neuronal avec quantité de calcul réduite.
CY2425B1 (en) 2,4-Diaminopyrimidine derivatives.
MXPA00007394A (es) Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.
SI1107795T1 (en) Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
HK1051533A1 (en) Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use.
PL348036A1 (en) Tissue paper product, and process for making the product
ZA200109607B (en) Treated closures 3.
ZA9710070B (en) Refundable travellers cheques.
ZA200109605B (en) Treated closures 2.
GB2336347B (en) Roller conveyor or roller conveyor section
ZA200101188B (en) DNAzymes and methods for treating restenosis.
ZA997525B (en) Conveyor belting with modified fabric.
ZA972302B (en) 1,25-Dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives.
SG43383A1 (en) N n-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2- propanamine dimaleate
Peter Johnson
EP0653438A3 (fr) Composés oligonucléotidiques, leur production et leur utilisation.